Media Summary: Doris Hansen, MD, of the Moffit Cancer Center in Tampa, Florida, spoke with Blood Cancers Today on findings from a ... Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses Doris K. Hansen, MD, Moffitt Cancer Center, Tampa, FL, provides an overview of the real-world outcomes of patients with ...
Valuable Predictors Identified For Ide Cel Therapy In Multiple Myeloma - Detailed Analysis & Overview
Doris Hansen, MD, of the Moffit Cancer Center in Tampa, Florida, spoke with Blood Cancers Today on findings from a ... Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses Doris K. Hansen, MD, Moffitt Cancer Center, Tampa, FL, provides an overview of the real-world outcomes of patients with ... During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Hamza Hashmi, MD, Medical University of South Carolina, Charleston, SC, explains the findings of a study investigating factors ... Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the development of an inflammatory risk score to
Nina Shah, MD, University of California, San Francisco, CA, discusses findings from a subanalysis of the Phase II KarMMa trial ... Dr. Krina Patel discusses the findings of the KarMMa-3 study, which focused on comparing the effectiveness of Idecabtagene ... This year we saw the FDA approval of idecabtagene vicleucel ( Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the roles of idecabtagene ... Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the findings of a study investigating the impact of the ... Ciara Freeman, MD, PhD, Moffitt Cancer Center, Tampa, FL, discusses the development of a real-time, multimodal artificial ...
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses real-world experiences with idecabtagene vicleucel ( Larry D Anderson, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX, discusses the updated results from ... Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses findings from the Phase II KarMMa study ... ASH Review March 13, 2026 Presented by: Noffar Bar, MD.
